Neurology

Treatment Strategies and Managing Expectations

At a Glance

Paraneoplastic polyneuropathy is treated on two tracks: controlling the cancer that triggers the immune response and calming the immune attack on nerves. Prompt treatment may halt progression, but recovery depends on antibody type and how much nerve damage has occurred.

Treating paraneoplastic polyneuropathy (PPN) requires a “dual-track” strategy. You and your medical team are fighting on two fronts at once: you must treat the cancer that is triggering the immune response, and you must use therapies to quiet the immune system from attacking your nerves ^[1]^[2].

The Primary Treatment: Controlling the Cancer

Evaluating and treating the underlying tumor is usually the most important disease-directed step in PPN management. Because the tumor is the “source” of the proteins that confuse your immune system, removing or shrinking it addresses the trigger ^[3].

Halting Progression: For many patients, successful cancer treatment (surgery, radiation, or chemotherapy) helps stop the nerve damage from getting worse ^[4]^[5].
Important Caveat on Cancer Therapy: Some modern cancer treatments, specifically immune-checkpoint inhibitors, work by activating the immune system against the tumor. These drugs can sometimes trigger or worsen paraneoplastic neurologic syndromes ^[6]. The decision to use them requires careful, explicit discussion between your oncology and neurology teams.

The Immune Treatment: Protecting the Nerves

While the oncology team works on the tumor, a neurologist may use immunotherapy to dampen the immune attack. There is no universally effective sequence or “ladder” of these drugs; treatment depends heavily on your specific phenotype, severity, and specialist judgment ^[2]^[7].

Corticosteroids: High-dose anti-inflammatory drugs that broadly quiet the immune response ^[8]^[9].
IVIG (Intravenous Immunoglobulin): Infusions of healthy donor antibodies to help modulate the immune system ^[7].
Plasma Exchange (Plasmapheresis): A filtering process that removes harmful antibodies from the blood ^[8]^[10].
Targeted Immunosuppression: More potent drugs like rituximab or cyclophosphamide may be used to target specific immune cells, depending on your antibody type ^[11]^[10].

Crucial Safety and Monitoring Context

These immunosuppressive treatments carry significant risks that must be carefully managed:

High-dose steroids can cause bone density loss, metabolic changes, and infection risk.
IVIG and plasma exchange carry risks of infusion complications, blood pressure changes, and thrombotic (clotting) events.
Rituximab and cyclophosphamide require rigorous laboratory monitoring for severe infection risk, cytopenias (low blood cell counts), hepatitis B reactivation, bladder toxicity, and potential fertility effects. Your team must review your vaccination status and infection screening before beginning ^[10].

The Importance of Prompt Treatment

Nerve damage from an immune attack can happen rapidly, and once a nerve cell is lost, it usually cannot be replaced ^[12]. Treating the condition as promptly as possible offers the best chance of preventing permanent disability ^[13]^[14].

Managing Expectations for Recovery

It is vital to have an honest conversation with your team about what “success” looks like. In cases involving intracellular antibodies (like Anti-Hu), the immune system uses T-cells that often permanently damage nerve cells ^[12]^[15].

The Goal is “Stable”: Because these nerve cells are often destroyed, the primary goal of treatment is frequently to reach a state where the symptoms stop progressing ^[5]^[16].
Surface Antibodies: If your tests show “surface” antibodies, the chance of a functional recovery may be higher, though outcomes still vary significantly ^[17]^[18].

Even if your symptoms do not fully reverse, stopping the progression is a major victory. It can mean the difference between maintaining the ability to walk with an aid versus losing that mobility entirely ^[19]^[20].

Common questions in this guide

How is paraneoplastic polyneuropathy treated?

Treatment usually has two parts: control the cancer that is triggering the immune response and reduce the immune attack on the nerves. Cancer treatment may include surgery, radiation, or chemotherapy, while neurologists may consider steroids, IVIG, plasma exchange, or other immune-suppressing medicines.

Can treating the cancer improve paraneoplastic polyneuropathy?

Treating the cancer can sometimes stop or slow further nerve damage, especially when the tumor is removed or controlled. It may not reverse nerve cells that have already been destroyed, so the treatment goal is often to stabilize symptoms and preserve function.

Which immune treatments may be used for PPN?

Options include high-dose corticosteroids, IVIG, and plasma exchange. Depending on the antibody type, severity, and response, specialists may also use rituximab or cyclophosphamide; there is no single treatment sequence that works for everyone.

What are the risks of immunotherapy for paraneoplastic polyneuropathy?

Risks vary by treatment. Steroids can raise infection risk and affect bones and metabolism; IVIG and plasma exchange can cause infusion, blood-pressure, or clotting problems; rituximab and cyclophosphamide can cause serious infections, low blood counts, hepatitis B reactivation, bladder toxicity, or fertility effects. Teams may check blood tests, vaccination status, and infections before and during therapy.

What does an Anti-Hu or intracellular antibody mean for recovery?

Intracellular antibodies such as Anti-Hu often cause immune damage involving nerve cells, which may be permanent, so the realistic goal may be stopping progression rather than full recovery. Surface antibodies can be associated with a better chance of functional recovery, but outcomes still vary.

Why should oncology and neurology coordinate PPN treatment?

Cancer treatment and immune treatment can affect each other, and immune-checkpoint drugs may sometimes trigger or worsen paraneoplastic neurologic syndromes. Close coordination between oncology and neurology helps the team weigh cancer control, nerve protection, side effects, and monitoring.

Get notified when new evidence is published on paraneoplastic polyneuropathy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References (20)

1
Single-Center Retrospective Analysis of Paraneoplastic Syndromes with Peripheral Nerve Damage.
Tian J, Cao C, Miao R, et al.
Brain sciences 2022; (12(12)) doi:10.3390/brainsci12121656.
PMID: 36552116
2
Double trouble: para-neoplastic anti-PCA-2 and CRMP-5-mediated small fibre neuropathy followed by chorea associated with small cell lung cancer and evolving radiological features.
Waheed W, Boyd J, Khan F, et al.
BMJ case reports 2016; (2016()).
PMID: 27571910
3
Paraneoplastic Neuropathies: What's New Since the 2004 Recommended Diagnostic Criteria.
Zoccarato M, Grisold W, Grisold A, et al.
Frontiers in neurology 2021; (12()):706169 doi:10.3389/fneur.2021.706169.
PMID: 34659082
4
A Rare Case of Sensory Neuropathy Associated with Transitional Cell Carcinoma of the Bladder.
Ketineni S, Kodali S, Gorantla S
Case reports in oncology 2020; (13(3)):1397-1401 doi:10.1159/000510742.
PMID: 33442362
5
Sensory neuronopathy associated with cholangiocarcinoma diagnosed 6 years after symptom onset.
Rossor AM, Blake J, Pissanou T, Reilly MM
BMJ case reports 2017; (2017()) doi:10.1136/bcr-2016-217844.
PMID: 29269356
6
Successful Treatment of Paraneoplastic Neuropathy and Pruritis With Scrambler Therapy: A Case Report.
Murphy TK, Pardo CA, Roda RH, et al.
Cureus 2022; (14(7)):e26861 doi:10.7759/cureus.26861.
PMID: 35978756
7
A case of IVIg responsive paraneoplastic SOX1 peripheral neuropathy in a male with breast carcinoma.
Beer R, O'Gorman C, Horwood K, Blum S
Journal of neuroimmunology 2021; (352()):577492 doi:10.1016/j.jneuroim.2021.577492.
PMID: 33508769
8
Rapidly Progressive Paraneoplastic Neuropathy Associated with Renal Cell Carcinoma: A Case Report.
Shah D, Trivedi J, Vernino S, Khan S
Journal of cancer science and clinical therapeutics 2022; (6(3)):333-335 doi:10.26502/jcsct.5079171.
PMID: 36685138
9
Sensory neuronopathies: A case series and literature review.
Sancho Saldaña A, Mahdi-Rogers M, Hadden RD
Journal of the peripheral nervous system : JPNS 2021; (26(1)):66-74 doi:10.1111/jns.12433.
PMID: 33491284
10
Diffuse Large B-Cell Lymphoma Presenting as an Unusual Paraneoplastic Neurologic Syndrome Affecting the Central and Peripheral Nervous Systems.
Sorrentino AD, Kelkar AH, Dang NH
Cureus 2021; (13(4)):e14590 doi:10.7759/cureus.14590.
PMID: 34036008
11
A Case Report of Pediatric Paraneoplastic Dysautonomia.
Harer K, Mann J, Muhlbauer N, et al.
Pediatric emergency care 2020; (36(12)):e742-e744 doi:10.1097/PEC.0000000000001558.
PMID: 30045352
12
Neurologic Autoimmunity in the Era of Checkpoint Inhibitor Cancer Immunotherapy.
Zekeridou A, Lennon VA
Mayo Clinic proceedings 2019; (94(9)):1865-1878 doi:10.1016/j.mayocp.2019.02.003.
PMID: 31358366
13
Identifying a therapeutic window in acute and subacute inflammatory sensory neuronopathies.
Antoine JC, Robert-Varvat F, Maisonobe T, et al.
Journal of the neurological sciences 2016; (361()):187-91.
PMID: 26810539
14
Sensory Neuronopathies: Clinical Presentation, Management, and Outcome.
Maniyar A, Ojha PT, Chheda A, et al.
Annals of Indian Academy of Neurology 2024; (27(5)):506-511 doi:10.4103/aian.aian_303_24.
PMID: 39344260
15
Immune-mediated disorders.
Höftberger R, Lassmann H
Handbook of clinical neurology 2017; (145()):285-299 doi:10.1016/B978-0-12-802395-2.00020-1.
PMID: 28987176
16
Phase II trial of natalizumab for the treatment of anti-Hu associated paraneoplastic neurological syndromes.
Bastiaansen AEM, de Jongste AHC, de Bruijn MAAM, et al.
Neuro-oncology advances 2021; (3(1)):vdab145 doi:10.1093/noajnl/vdab145.
PMID: 34693289
17
Pathogenesis and immunopathology of paraneoplastic disorders.
Quinot V, Höftberger R
Handbook of clinical neurology 2024; (200()):33-54 doi:10.1016/B978-0-12-823912-4.00027-X.
PMID: 38494287
18
Paraneoplastic Disorders.
Lancaster E
Continuum (Minneapolis, Minn.) 2017; (23(6, Neuro-oncology)):1653-1679 doi:10.1212/CON.0000000000000542.
PMID: 29200116
19
Paraneoplastic Myeloneuropathies: Clinical, Oncologic, and Serologic Accompaniments.
Shah S, Vazquez Do Campo R, Kumar N, et al.
Neurology 2021; (96(4)):e632-e639 doi:10.1212/WNL.0000000000011218.
PMID: 33208548
20
Expanded Clinical Phenotype, Oncological Associations, and Immunopathologic Insights of Paraneoplastic Kelch-like Protein-11 Encephalitis.
Dubey D, Wilson MR, Clarkson B, et al.
JAMA neurology 2020; (77(11)):1420-1429 doi:10.1001/jamaneurol.2020.2231.
PMID: 32744608

This page is for informational purposes only and does not constitute medical advice about paraneoplastic polyneuropathy. Your oncology and neurology teams should tailor treatment and monitoring to your cancer, antibody findings, and overall health.

Guide Contents